CARES-310
Regimen
- Experimental
- camrelizumab + rivoceranib (apatinib)
- Control
- sorafenib
Population
Unresectable or metastatic hepatocellular carcinoma, no prior systemic therapy
Key finding
mOS 22.1 vs 15.2 mo (HR 0.62, 95% CI 0.49-0.80, p<0.0001) — longest mOS reported in any 1L HCC phase 3 to date; mPFS 5.6 vs 3.7 mo (HR 0.52); etiology HBV ~77% (Asian-dominant enrollment); FDA approved March 2024
Source: PMID 37499670